The major limitation of our study was the low sample sizes for the luminal A, luminal B, and HER2 subgroups; thus, a follow-up study with larger sample sizes of all BC subtypes, including non-TNBC (luminal A, luminal B, and HER2), would further strengthen our findings. This evidence concerns the gene ERBB2 and breast cancer.